Literature DB >> 21569009

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.

Tomohiro Morio1, Yoshiko Atsuta, Daisuke Tomizawa, Tokiko Nagamura-Inoue, Koji Kato, Tadashi Ariga, Keisei Kawa, Kazutoshi Koike, Hisamichi Tauchi, Michiko Kajiwara, Toshiro Hara, Shunichi Kato.   

Abstract

We report the results of umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between 1998 and 2008 in Japan; severe combined immunodeficiency (SCID, n = 40), Wiskott-Aldrich syndrome (WAS, n = 23), chronic granulomatous disease (n = 7), severe congenital neutropaenia (SCN, n = 5) and other immunodeficiencies (n = 13). Five-year overall survival (5-year OS) for all patients was 69% [95% confidence interval (CI), 57-78%], and was 71% and 82% for SCID and WAS, respectively. The main cause of death before day 100 was infection (17/19), while that after day 100 was graft-versus-host disease (GVHD) (5/7). Using multivariate analyses, pre-transplant infection, no conditioning, ≥ 2 human leucocyte antigen (HLA) mismatches or diagnosis other than SCID, SCN or WAS were all associated with poor prognosis. Reduced-intensity conditioning was associated with decreased overall mortality compared with myeloablative therapy. The cumulative incidence of grade 2-4 acute GVHD at day 100 was 28% (95% CI, 19-38%), and that of chronic GVHD at day 180 was 13% (95% CI, 7-23%). We conclude that UCBT should be considered for PID patients without an HLA-matched sibling. The control of pre-transplant infection and selection of HLA-matched donors will lead to a better outcome.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21569009     DOI: 10.1111/j.1365-2141.2011.08735.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Nationwide survey of patients with primary immunodeficiency diseases in Japan.

Authors:  Masataka Ishimura; Hidetoshi Takada; Takehiko Doi; Kousuke Imai; Yoji Sasahara; Hirokazu Kanegane; Ryuta Nishikomori; Tomohiro Morio; Toshio Heike; Masao Kobayashi; Tadashi Ariga; Shigeru Tsuchiya; Shigeaki Nonoyama; Toshio Miyawaki; Toshiro Hara
Journal:  J Clin Immunol       Date:  2011-09-29       Impact factor: 8.317

2.  B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.

Authors:  Satoru Kumaki; Yoji Sasahara; Yoshiro Kamachi; Hideki Muramatsu; Tomohiro Morio; Kumiko Goi; Kanji Sugita; Tomonari Urabe; Hidetoshi Takada; Seiji Kojima; Shigeru Tsuchiya; Toshirou Hara
Journal:  Int J Hematol       Date:  2013-08-17       Impact factor: 2.490

3.  Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.

Authors:  Eun Sang Yi; Young Bae Choi; Na Hee Lee; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Eun-Sook Kang; Yae-Jean Kim; Keon Hee Yoo
Journal:  J Clin Immunol       Date:  2018-08-27       Impact factor: 8.317

Review 4.  Hematopoietic stem cell transplantation for severe congenital neutropenia.

Authors:  James A Connelly; Sung W Choi; John E Levine
Journal:  Curr Opin Hematol       Date:  2012-01       Impact factor: 3.284

5.  Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985-2016.

Authors:  Satoshi Miyamoto; Katsutsugu Umeda; Mio Kurata; Masakatsu Yanagimachi; Akihiro Iguchi; Yoji Sasahara; Keiko Okada; Takashi Koike; Reo Tanoshima; Masataka Ishimura; Masafumi Yamada; Maho Sato; Yoshiyuki Takahashi; Michiko Kajiwara; Hiroshi Kawaguchi; Masami Inoue; Yoshiko Hashii; Hiromasa Yabe; Koji Kato; Yoshiko Atsuta; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2022-01-04       Impact factor: 8.317

6.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

7.  Mesenchymal Stem Cells and Mononuclear Cells From Cord Blood: Cotransplantation Provides a Better Effect in Treating Myocardial Infarction.

Authors:  Gecai Chen; Aihuan Yue; Hong Yu; Zhongbao Ruan; Yigang Yin; Ruzhu Wang; Yin Ren; Li Zhu
Journal:  Stem Cells Transl Med       Date:  2016-01-21       Impact factor: 6.940

8.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317

Review 9.  [Advances in newborn screening and immune system reconstitution of severe combined immunodeficiency].

Authors:  Shumin Huang; Zhengyan Zhao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-25

Review 10.  Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

Authors:  David Buchbinder; Diane J Nugent; Alexandra H Fillipovich
Journal:  Appl Clin Genet       Date:  2014-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.